15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 26 firms covering Vertex Pharmaceuticals Inc, 21 rate it Buy or better, 4 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets span $350.00 to $641.00, a moderate spread. The average target of $555.12 sits 13% above the current $490.67. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $4.81 next quarter toward $21.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS26 ratings
Moderate Buy
Strong Buy00%
Buy2181%
Hold415%
Sell14%
Strong Sell00%
Based on 26 analysts giving stock ratings to Vertex Pharmaceuticals Inc.
As of Jul, 21 of 26 firms rate VRTX a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
VRTX EPS & revenue forecast
EPS · NEXT QUARTER
$4.81
Range $3.40 – $5.20 · 16 analysts · +0% YoY
Next period, 16 analysts expect Vertex Pharmaceuticals Inc to earn $4.81 a share (range $3.40 – $5.20), versus $4.80 a year earlier. Full-year consensus is $18.96, growing to $21.31 the year after.
REVENUE · NEXT QUARTER
$3.4B
Range $3.3B – $3.4B · 16 analysts · +9% YoY
Revenue is expected to reach $3.4B (range $3.3B – $3.4B), +9.2% year-over-year. Full-year consensus is $13.0B, rising to $14.3B next year.
Top analysts covering Vertex Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRTX.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$641.00+30.6% to target
Overall win rate
46%
+ Follow
#2
Joseph Stringer
Needham · Rank #168
Hold
No targeton VRTX
Overall win rate
36%
+ Follow
#3
Greg Harrison
Scotiabank · Rank #177
Hold
$558.00+13.7% to target
Overall win rate
38%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$598.00+21.9% to target
Overall win rate
41%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #302
Buy
$600.00+22.3% to target
Overall win rate
32%
+ Follow
VRTX stock forecast FAQ
What is VRTX's average 12-month price target?+
The 17 analysts with a live target average $555.12 for Vertex Pharmaceuticals Inc over the next 12 months, ranging from a $641.00 high to a $350.00 low.
Is VRTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 26 analyst ratings, 21 are Buy or Strong Buy, 4 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for VRTX?+
The Street-high target is $641.00 (HC Wainwright & Co.), and the Street-low is $350.00 (Baird). The average of all 17 active targets is $555.12.
How many Wall Street analysts cover VRTX?+
26 analysts have an active rating on Vertex Pharmaceuticals Inc, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering VRTX?+
Among analysts who currently cover VRTX, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $641.00 target.
What is Vertex Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $4.81 per share (range $3.40 – $5.20) across 16 analysts. Full-year EPS is projected at $18.96, rising to $21.31 the following year.
How much revenue is Vertex Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $3.4B (range $3.3B – $3.4B). Full-year revenue is projected at $13.0B, growing to $14.3B next year.
Have analysts been upgrading or downgrading VRTX lately?+
As of Jul, 21 of 26 firms rate VRTX a Buy (4 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
